Moxonidine is a new antihypertensive agent whose mechanism of action appears to involve specific stimulation of imidazoline receptors resulting in an inhibition of the activity of the central and peripheral sympathetic nervous system. The drug seems to behave neutrally with respect to plasma lipid parameters. However, there are no data on the effects of moxonidine on the lowdensity lipoprotein (LDL) subclass pattern or on the LDL oxidation susceptibility, both of which are known to play a prominent role in the pathogenesis of atherosclerosis. Thus, we undertook the present study to examine the influence of moxonidine on the LDL subspecies profile and their susceptibility to copper-induced oxidative modification in 20 hypertensive patients (11 men, 9 women) aged 38-61 years. Moxonidine administered at a dose of 0.4 mg daily for 8 weeks produced a signifi-
Introduction
It is well known that some antihypertensive agents, especially diuretics in high dosage and beta-blockers, have unfavourable effects on plasma lipids, including elevation of triglycerides and total cholesterol and reduction of high-density lipoprotein cholesterol (HDL-C). [1] [2] [3] [4] Additionally, it has been shown that beta-blocker use may predispose to expression of a relatively atherogenic lipoprotein subclass profile, as it is associated with a predominance of smaller, denser, low-density lipoprotein (LDL) particles and less HDL mass. 5, 6 Since an overview of all hypertension trials has shown that antihypertensive treatment does lead to a less than expected reduction in coronary heart disease (CHD) event rates, 7, 8 it is tempting to suggest that the adverse effects of the study drugs on lipid metabolism may have offset the potential benefit of blood pressure (BP) reduction. The selective imidazoline-I 1 -receptor agonists, a recently introduced class of antihypertensive agents, offers an innovative therapeutic approach to the treatment of hypertension. 9 Moxonidine, the first drug of this class, stimulates imidazoline I receptors in the medulla, thereby reducing central sympathetic drive and attenuating peri-cant decrease in both systolic and diastolic blood pressure (from 147 ؎ 10 to 131 ؎ 11 mm Hg, P Ͻ 0.001, and from 98 ؎ 4.5 to 86 ؎ 5 mm Hg, P Ͻ 0.001, respectively). No significant change in plasma lipid profile was observed after moxonidine administration. Additionally, no change in the susceptibility of LDL subclasses to copper-induced oxidative modification was noticed. Finally, drug therapy was not followed by any change in either LDL phenotype or in mass and composition of the three LDL subfractions. We conclude, that unlike other antihypertensive drugs, such as beta-blockers which may predispose to expression of a relatively atherogenic lipoprotein subclass pattern, moxonidine does not affect either plasma lipid parameters or lipoprotein composition.
pheral vascular resistance. Moreover, the reduced sympathetic drive results in lower concentrations of catecholamines and renin. 10, 11 Randomised comparative studies have shown that the efficacy of moxonidine as monotherapy is similar to that of other antihypertensive drugs. 12 In clinical studies moxonidine has been found to behave neutrally with respect to plasma lipid parameters. [12] [13] [14] However, there are no data on the effects of moxonidine on the LDL subclass pattern or on the LDL oxidation susceptibility, both of which are known to play a prominent role in the pathogenesis of atherosclerosis. Thus, we undertook the present study to examine the influence of moxonidine on the LDL subspecies profile and their susceptibility to copperinduced oxidative modification in patients with idiopathic hypertension.
Materials and methods
Twenty patients (11 male, 9 female) aged 38-61 years with mild/moderate arterial hypertension were studied. No patient had clinical or biochemical evidence of diabetes mellitus, thyroid, hepatic, or renal disease. Additionally, none of them was taking any lipid lowering drugs or any other medication known to affect lipid metabolism, including hormonal therapy. Individuals known to ingest more than two alcoholic drinks or to take vitamin supplements were excluded from the study. To avoid any possible effects of diet on the susceptibility of the LDL subfractions to oxidation, all subjects were advised to avoid altering their dietary habits throughout the study.
After a wash-out period of at least 4 weeks for the patients on antihypertensive drugs, moxonidine was given at a dose of 0.4 mg/day for 8 weeks. Before and after treatment BP was measured by a calibrated sphygmomanometer as triplicate measurements after the patients had been sitting for 5 min. In addition to BP measurements, pulse rate was recorded and venous blood was obtained after a 14 h overnight fast for the determination of plasma lipid parameters.
Subfractionation of LDL with density gradient ultracentrifugation was performed and the susceptibility of LDL subclasses to copper-induced oxidative modification was tested.
Subfractionation of low-density lipoprotein
Venous blood samples were collected from overnight fasting donors in tubes containing 0.001% Na 2 EDTA. Immediately after collection of plasma, 1.3 mM EDTA and 50 g/ml of gentamicin were added and plasma was stored at 4°C in order to prevent metal cation catalysed lipoprotein oxidation and microbial growth. Within 24 h from its collection, plasma was submitted to density gradient ultracentrifugation in a Beckman ultracentrifuge at 40 000 rpm, 14°C for 24 h, using a Beckman SW41 Ti rotor as previously described. 15 Construction of a discontinuous density gradient at ambient temperature was initiated by pumping 3 ml of plasma into the bottom of the tube. The density of the plasma was raised to 1.10 g/ml by dissolution of 0.42 g KBr. The plasma was then successively overlayered by four solutions of decreasing density (2 ml of d = 1.065 g/ml, 3 ml of d = 1.035 g/ml, 3 ml of d = 1.019 g/ml and 1.0 ml of d = 1.006 g/ml). After ultracentrifugation, 30 fractions of 400 l were collected by successive aspiration with a precision pipette from the meniscus downwards. All fractions were analysed for their protein content. Subsequently, equal volumes of specific gradient fractions corresponding to d = 1.030-1.034 g/ml, d = 1.034 -1.041 g/ml and d = 1.041-1.048 g/ml were pooled to constitute the LDL 1 , LDL 2 and LDL 3 subfractions, respectively.
Oxidation of low-density lipoprotein subfractions
Before oxidation, LDL subfractions were dialysed to remove EDTA against two changes of a 200-fold volume of 10 mM phosphate buffered saline solution (PBS), pH 7.4 for 24 h at 4°C in the dark. From the dialysed LDL subfractions, a volume of 1 ml containing 100 g protein/ml PBS was oxidised in the presence of CuSO 4 , 5 M final concentration. The kinetics of the oxidation were determined by monitoring the increase in the 234 nm absorbance on a Perkin-Elmer L15 spectrophotometer, every 10 min for 3 h. The increase in absorbance is due to the formation of conjugated fatty acid hydroperoxides during the peroxidation of the polyunsaturated fatty acid content of LDL. The sigmoidal curve of the oxidation is divided into three consecutive phases, lag phase, propagation phase and decomposition phase. The lag time, the maximal rate of conjugated dienes formation, and the total amount of dienes formed were calculated as previously described. 16 The relative electrophoretic mobility (REM) of the oxidised subfractions was determined by agarose gel electrophoresis on agarose gels [Lipo + Lp(a), Sebia].
Analytical methods
Total plasma cholesterol and triglyceride levels were measured by enzymatic colorimetric assays using an RA 1000 analyser (Technicon Instruments, NY, USA). HDL-cholesterol levels were also determined by the same method after precipitation of apoB-containing lipoproteins with magnesium-dextran sulphate. LDL-cholesterol levels were calculated using the Friedewald formula. 17 Plasma lipoprotein (a) [Lp(a)] levels were measured in duplicate using a monoclonal anti-Lp(a) antibody technique by the enzyme immunoassay Macra Lp(a) (Terumo Medical Corporation Diagnostic Division, Elkton, MD, USA). The lower limit of detectability was 0.8 mg/dL. Plasma apoAl and apoB were measured by immunonephelometry with the aid of a Beckman array analyser (Beckman Instruments, CA, USA). The cholesterol, phospholipid and triglyceride content of each lipoprotein subfraction was determined enzymatically using the BioMerieux kits. The protein content of the gradient fractions and lipoprotein subfractions was determined by the BCA method. Lipoprotein mass in each subfraction was calculated as the sum of the concentrations of the individual components (cholesterol, triglyceride, phospholipid and protein) and allowed the determination of the percent chemical composition. 16 
Statistical analysis
Data were expressed as mean ± s.d., except for Lp(a), which was expressed in terms of median and range. Statistical analysis was performed using paired or unpaired Student's t-test or Wilcoxon signed-rank test. A P value of less than 0.05 was considered to be significant.
Results
Moxonidine produced a significant decrease in both systolic and diastolic BP (from 147 ± 10 to 131 ± 11 mm Hg, P Ͻ 0.001, and from 98 ± 4.5 to 86 ± 5 mm Hg, P Ͻ 0.001, respectively) while no significant change in heart rate was noticed. As shown in Table  1 , drug administration was not followed by any significant change in plasma lipid parameters.
Mass profile and chemical composition of the LDL subfractions
The total LDL mass (calculated as the sum of the mass of the 3 LDL subfractions) was 225.6 ± 75.3 mg/dL and was not significantly altered after moxonidine treatment, 204.7 ± 56.3 mg/dL. The major LDL subfraction in our patients was LDL 2 hav- ing a mass of 112.2 ± 50.6 mg/dL, significantly higher compared to LDL 1 and LDL 3 (P Ͻ 0.001 for both comparisons). The mass of LDL 1 was also significantly higher compared to LDL 3 (P Ͻ 0.001) ( Table 2 ). Moxonidine administration did not alter the mass of each LDL subfraction (Table 2) and consequently, the mass distribution profile was not significantly influenced ( Figure 1) . Additionally, as shown in Table 2 , moxonidine did not alter the weight % content of cholesterol, triglycerides, phospholipids and protein of each LDL subfraction.
Oxidation profile of LDL subfractions
The LDL subfractions were oxidised in the presence of 5 M Cu ++ under continuous monitoring of the absorbance at 234 nm. As shown in Table 3 , the LDL 1 subfraction either before or after treatment was more resistant to oxidation, since it had a greater lag time, lower rate of oxidation, lower total amount of dienes and REM values compared with the other two subfractions (P Ͻ 0.05 for comparisons of all parameters with those observed in LDL 2 or LDL 3 subfraction, either before or after treatment with moxonidine). As it was expected, the subfraction more susceptible to oxidation was the dense LDL 3 either before or after moxonidine treatment. It is important to note that drug treatment did not influence the susceptibility to oxidation of each LDL subfraction, since none of the oxidation parameters measured was significantly altered after treatment (Table 3 )
Discussion
Because of the frequent association of dyslipidaemia with hypertension, plasma lipid parameters should be measured in hypertensive patients. In subjects who display any lipid abnormalities, thiazide diuretics and beta-blockers may not be an appropriate first-step treatment, since they appear to alter the lipid profile unfavourably, at least in short-term studies. [1] [2] [3] [4] Additionally, beta-blocker use is associated with a predominance of smaller, denser LDL particles and less HDL mass, 5, 6, 18 lipoprotein changes that might be expected to increase coronary artery 19 and offset the beneficial effects of antihypertensive therapy on cardiovascular morbidity and mortality. 7, 8 It has recently been suggested that moxonidine seems to be a logical choice for hypertensive patients with coexistent glucose intolerance or dyslipidaemia, 20 as in clinical studies moxonidine has been proved to have neutral or even beneficial effects on lipid and carbohydrate metabolism. [12] [13] [14] In this setting, we have shown for the first time that the drug does not affect plasma lipid parameters, LDL subfraction distribution, or LDL subclasses composition and oxidability.
The neutral effect of moxonidine on plasma lipid parameters is in agreement with the findings previously reported with other centrally acting drugs and especially with clonidine, which has been found to minimally influence lipid levels. 21, 22 The absence of a significant change in plasma triglycerides, unlike the significant increase in plasma triglycerides observed after beta-blockage use could partly explain the lack of a significant change in LDL pattern, taking into account that plasma triglycerides are emerging as the most important determinant of the LDL subfraction profile. 18, 23 It has recently been reported that LDL isolated from patients with essential hypertension exhibits increased propensity for oxidation. 24 The increased LDL oxidability in hypertensive patients may be related to angiotensin II, which has been shown to have a stimulatory effect on copper-induced oxidation of LDL, as well as on LDL degradation by macrophages. 24 Furthermore, the increased susceptibility of hypertensive patients' LDLs to lipid peroxidation decreased significantly after treatment with angiotensin-converting enzyme inhibitors, which may act through the suppression of local production of angiotensin II in the arterial wall. 24 However, even though moxonidine could lower serum concentrations of catecholamines and renin, [25] [26] [27] no significant change in the susceptibility of LDL subclasses to copper-induced oxidative modification was found. Similarly, atenolol, which can also reduce plasma renin activity had no effect on the oxidation resistance of LDL, [28] [29] [30] while nifedipine and other calcium channel blockers displayed a significant dose-dependent capacity to protect LDL during copper-induced oxidation, 28, 31 suggesting that calcium antagonists may potentially exert antiatherosclerotic properties via a reduction of the oxidative modification of LDL.
We conclude that unlike other antihypertensive drugs moxonidine does not affect plasma lipid parameters, LDL subfraction distribution, or LDL subclasses composition and oxidability.
